Trial Profile
Switching to aflibercept in patients with neovascular age-related macular degeneration not responding to anti-VEGF treatment: a pilot study [Overstappen op aflibercept bij patiënten die niet reageren op anti-VEGF therapie]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 19 Nov 2015 Status changed from planning to completed as per Netherlands Trial Register record.
- 08 Oct 2013 New trial record